

Special Issue

Therapeutic Vaccination of HIV-Infected Patients 2.0

Message from the Guest Editors

In 2019, 38 million people worldwide were living with human immunodeficiency virus 1 (HIV-1), 1.7 million new infections were reported, and almost 1 million patients died of AIDS. Despite the efforts of numerous research teams all around the world, no effective HIV-1 vaccine is available to date. The extremely high genetic variability of the virus and its ability to suppress protective immune responses hinder the development of a vaccine based on conventional methodologies. Another obstacle is the lack of adequate laboratory models to test potential vaccines on human tissue in a high-throughput manner. In line with these considerations, we would like to encourage the submission of works on the recent advances in the development of novel therapeutic vaccines for the treatment of HIV to this Special Issue. Studies using vaccine immunotherapy, adoptive cell transfer, CAR-T cells, HIV-associated and HIV-specific antigen stimulation of immune/antigen-presenting cells, and the use of nucleic acid transfer are welcome. Adding new information about these subjects may improve the design and the efficiency of new therapeutic vaccination strategies of HIV.

Guest Editors

Dr. Wilfried Posch

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

Prof. Dr. Doris Wilflingseder

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

Deadline for manuscript submissions

closed (30 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/59251

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).